GHK-Cu
GHK-Cu is a human copper-binding tripeptide with the best evidence for topical skin repair and wound healing, including Mulder 1994 diabetic ulcer data showing 98.5% median closure versus 60.8% vehicle. Systemic injection remains unproven in human trials.
GHK-Cu scored 5.9 / 10 (👍 Worth trying) on the BioHarmony scale as a Substance → Peptide → Growth / Repair Peptide.
What It Is
GHK-Cu is the copper-bound form of the human tripeptide glycyl-L-histidyl-L-lysine. Think of GHK as a small carrier peptide and Cu2+ as the copper ion it holds. Together, GHK-Cu acts less like a stimulant and more like a repair signal: it helps deliver copper into contexts where collagen, elastin, glycosaminoglycans, antioxidant enzymes, keratinocytes, fibroblasts, and wound-bed remodeling are already active.
The strongest human evidence is topical. In diabetic plantar ulcers, Mulder 1994 reported 98.5% median ulcer-area closure with topical GHK-Cu gel versus 60.8% with vehicle. Ex vivo delivery work also supports topical use: Hostynek 2011 measured copper-tripeptide penetration through human skin, and Li 2015 found microneedle pretreatment greatly increased GHK-Cu delivery through human skin over 9 hours.
The weaker lane is systemic use. Peptide communities use subcutaneous GHK-Cu for longevity, stem-cell activation, DNA repair, hair, nerve repair, and inflammation, but the audit did not confirm a newer GHK-Cu-specific human RCT or meta-analysis that upgrades systemic claims. Pickart 2014 and Pickart 2018 support broad gene-expression and repair pathways; they do not prove that 1-2 mg/day injections extend lifespan, improve cognition, or regenerate tissue in humans.
That split is the whole report. GHK-Cu is a good topical skin-repair peptide with legitimate wound and cosmetic evidence. It is also a speculative systemic peptide where sourcing, copper status, sterility, and overclaiming matter.
Terminology
For a regulatory cross-reference, see the FDA 503A bulk-substance update.
- GHK: Glycyl-L-histidyl-L-lysine, the three-amino-acid human peptide before copper binding.
- Cu2+: Copper in the divalent oxidation state. GHK binds this copper ion to form GHK-Cu.
- GHK-Cu: The copper-chelated GHK complex, usually treated as the biologically active copper-peptide form.
- Copper tripeptide-1: Cosmetic-ingredient naming commonly used for GHK-Cu in skincare.
- Prezatide copper: A drug-name synonym for GHK-Cu used in regulatory and ingredient databases.
- SOD: Superoxide dismutase, an antioxidant enzyme family that depends on metal cofactors.
- TIMP-1 / TIMP-2: Tissue inhibitors of matrix metalloproteinases, proteins that help regulate matrix breakdown.
- MMP: Matrix metalloproteinase, an enzyme family that breaks down collagen and extracellular matrix.
- Fibroblast: A connective-tissue cell that produces collagen, elastin, and ground-substance molecules.
- Keratinocyte: The main epidermal skin cell. GHK-Cu can affect keratinocyte proliferation and migration in skin models.
- p63: A stemness-associated marker in basal keratinocytes. Kang 2009 reported increased p63 positivity with copper-GHK.
- PCNA: Proliferating cell nuclear antigen, a marker associated with cellular proliferation.
- SC injection: Subcutaneous injection, meaning injection into the fat layer under the skin.
- Microneedling: Controlled skin puncturing that increases topical ingredient delivery through the stratum corneum.
- Iontophoresis: Electrical delivery of charged molecules through the skin.
- Wilson's disease: A genetic copper-accumulation disorder; added copper exposure can be dangerous.
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 4 routes and 4 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Topical | Aqueous serum or cream containing GHK-Cu | 0.5-3% cream 1-2x/day in cosmetic and dermatology references | 0.05-2% serum daily; often stacked with Matrixyl, niacinamide, retinoids on alternate nights, and collagen peptides |
| Topical patch | LifeWave X39 style transdermal or photobiomodulation patch | No independent clinical dose standard confirmed | Daily patch placement, often on neck, spine, or acupoint-style locations |
| Subcutaneous injection | Lyophilized GHK-Cu powder reconstituted in bacteriostatic water | None confirmed; zero human injection RCTs found | 1-5 mg/day SC; most commonly 1-2 mg/day in 30-day cycles |
| Intranasal | Reconstituted peptide spray | None confirmed | 0.2-0.5 mg/day in niche peptide-community use |
Protocols
Skin and hair (daily topical default) Clinical
- Dose
- 0.5-3% topical serum or cream
- Frequency
- 1-2x/day
- Duration
- 8-12 weeks for wrinkle, firmness, and barrier endpoints; 3-6 months for scalp-hair experiments
Best evidence lane. Stack with niacinamide and collagen peptides; use retinoids on alternate nights to reduce pH and irritation conflicts.
Systemic longevity (injection, community) Anecdotal
- Dose
- 1-2 mg SC
- Frequency
- Daily
- Duration
- 30 days on / 30 days off, cycled
No human injection RCTs. Avoid in Wilson's disease, copper overload, pregnancy, lactation, active malignancy, and while using medically supervised copper chelation.
Post-microneedling / post-procedure Mixed
- Dose
- 2-3% GHK-Cu serum applied after clinician-cleared skin procedures
- Frequency
- 1-2x/day for 5-7 days
- Duration
- 5-7 days
Microneedling increases GHK-Cu delivery through skin per [Li 2015](https://pubmed.ncbi.nlm.nih.gov/25690343/). Use sterile products after needling and avoid questionable raw powders.
Hair loss (scalp topical) Mixed
- Dose
- 0.5-1% GHK-Cu topical
- Frequency
- Daily scalp application
- Duration
- 3-6 months
Mechanism and cosmetic hair-product evidence support follicle-adjacent use, but GHK-Cu should be considered adjunctive to minoxidil, microneedling, red light therapy, or finasteride when those are appropriate.
Use-Case Specific Dosing
| Use Case | Dose | Notes |
|---|---|---|
How this score is calculated →
Upside contribution: 3.18
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 3.5 | 0.875 | |
| Breadth of Benefits | 15% | 3.5 | 0.525 | |
| Evidence Quality | 25% | 3.0 | 0.750 | |
| Speed of Onset | 10% | 2.5 | 0.250 | |
| Durability | 10% | 2.5 | 0.250 | |
| Bioindividuality Upside | 15% | 3.5 | 0.525 | |
| Total | 3.175 |
Upside Rationale
GHK-Cu has its strongest upside when the reader wants skin beauty, wound healing, recovery repair and can use the intervention in the studied context. Mulder et al. 1994 gives the score a real evidence anchor, while Pickart et al. 2015 helps define where the effect is narrower or broader. The practical value is not magic; it is a specific lever that can matter when topical route, copper sensitivity, wound status, and sterile sourcing already point in the right direction. The upside is strongest when the mechanism, population, and outcome line up instead of borrowing confidence from neighboring claims. In practice, the intervention belongs in a stack only after higher-use basics are already stable.
Efficacy (3.5/5.0). Topical GHK-Cu has one clear clinical support point: Mulder 1994 reported 98.5% median area closure in diabetic plantar ulcers versus 60.8% with vehicle, plus lower ulcer infection incidence. Cosmetic skin evidence also points in the same direction, although several frequently cited Finkey, Leyden, and Abdulghani items are older, industry-adjacent, or not consistently PubMed-indexed. The score stays 3.5 because the topical signal is credible, delivery science is coherent, and collagen-remodeling mechanisms are consistent. It does not rise because systemic injection has zero confirmed human RCTs, and the audit found no recent large GHK-Cu human trial that upgrades efficacy.
Breadth of Benefits (3.5/5.0). GHK-Cu touches skin regeneration, wound healing, keratinocyte proliferation, fibroblast collagen signaling, glycosaminoglycan synthesis, hair-follicle-adjacent biology, inflammatory signaling, DNA-repair gene expression, antioxidant pathways, nerve-outgrowth signals, and anti-fibrotic myofibroblast biology. Pickart 2015 and Pickart 2018 explain why one copper-peptide signal can look broad across tissues. The breadth score holds at 3.5 because the mechanisms are unusually broad for a topical peptide. It does not move higher because the demonstrated human endpoint breadth is still concentrated in skin and wounds, not cognition, cardiovascular health, metabolism, or lifespan.
Evidence Quality (3.0/5.0). Evidence quality remains moderate: real topical clinical and ex vivo evidence, plus decades of mechanistic work, but meaningful conflict-of-interest and route-transfer problems. Hostynek 2011 and Li 2015 strengthen topical delivery confidence, while Ogorek 2025 reminds readers that GHK-Cu is hydrophilic and hard to move through the stratum corneum without formulation help. The audit found no Cochrane review, NICE guidance, USPSTF recommendation, or GHK-Cu-specific AAD endorsement. FDA also has no approved therapeutic indication. That authority gap caps confidence despite promising biology.
Speed of Onset (2.5/5.0). GHK-Cu is a weeks-to-months repair signal, not a same-day performance lever. Topical hydration and barrier feel can change within 1-2 weeks, especially in dry or disrupted skin. Firmness, wrinkle, collagen, and post-procedure texture changes usually require 8-12 weeks of consistent use. Wound-bed granulation can move faster when the tissue is injured and actively remodeling, which matches Mulder 1994. Systemic injection effects, when users report them, are often subtle and delayed. That timeline keeps speed at 2.5, below acute interventions like caffeine and below faster visible interventions like botulinum toxin or fillers.
Durability (2.5/5.0). GHK-Cu benefits are use-dependent. Topical improvements in hydration, firmness, and barrier function fade as skin turnover and collagen remodeling return toward baseline after discontinuation. Wound closure, once complete, is more durable because the wound has structurally healed, but that is different from ongoing anti-aging skin use. No human washout study establishes durable systemic injection effects. GHK-Cu looks like a maintenance signal rather than a one-time reset. That makes it more durable than pure moisturization but less durable than procedures that permanently alter tissue structure or habits that build transferable capacity.
Bioindividuality Upside (3.5/5.0). The best responders are older, photoaged, collagen-depleted, post-menopausal, post-procedure, scar-prone, or wound-healing-challenged users because the delta from baseline repair capacity is larger. Younger users with intact collagen turnover may see less visible change. GHK-Cu also depends on route: a well-formulated topical is not the same as a patch claim or a gray-market injection vial. Copper status matters too. Wilson's disease and copper-overload physiology flip copper from helpful cofactor to hazard. This strong responder segmentation keeps bioindividuality at 3.5 rather than a universal-benefit score.
Downside contribution: 2.27 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 2.0 | 0.600 | |
| Side Effect Profile | 15% | 2.0 | 0.300 | |
| Financial Cost | 5% | 1.5 | 0.075 | |
| Time/Effort Burden | 5% | 2.0 | 0.100 | |
| Opportunity Cost | 5% | 2.0 | 0.100 | |
| Dependency / Withdrawal | 15% | 1.0 | 0.150 | |
| Reversibility | 25% | 1.5 | 0.375 | |
| Total | 1.700 | |||
| Harm subtotal × 1.4 | 1.995 | |||
| Opportunity subtotal × 1.0 | 0.275 | |||
| Combined downside | 2.270 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 0.930 |
Downside Rationale
GHK-Cu still needs caution because the downside profile depends on topical route, copper sensitivity, wound status, and sterile sourcing, not only on the headline benefit. Safety, cost, and effort scores sit at 2, 1.5, and 2 out of 5, which means the tradeoff changes by user type. Mulder et al. 1994 supports the core benefit, but the same evidence base leaves gaps around long-term use, nonresponders, and people outside the studied population. The downside is not only adverse events; it is also cost, effort, sourcing quality, contraindications, and the chance of chasing the wrong lever. That makes screening and expectation-setting part of the intervention, not an optional afterthought. The downside is not only adverse events; it is also cost, effort, sourcing quality, contraindications, and the chance of chasing the wrong lever.
Safety Risk (2.0/5.0). Topical GHK-Cu safety looks good, but systemic and injectable use changes the risk profile. Li 2016 found GHK-Cu had low skin-irritation potential compared with several inorganic copper compounds in cellular biomarker testing. The bigger concerns are Wilson's disease, known copper overload, active malignancy caution because pro-repair and angiogenesis signals are not always desirable around tumors, pregnancy and lactation uncertainty, and injectable supply-chain risk. FDA's 2026 503A update also makes clear that compounding status is unsettled, not an efficacy or safety endorsement.
Side Effect Profile (2.0/5.0). Topical side effects are usually mild: redness, tingling, contact irritation, dryness when layered poorly, or rare green-blue discoloration from high copper exposure. Microneedling amplifies both delivery and irritation risk, so sterile product quality matters after skin barrier disruption. Injectable users report injection-site redness, soreness, induration, metallic taste, and occasional local discoloration, but those community reports are not a clean clinical safety database. Compared with retinoids, GHK-Cu is usually gentler topically. Compared with ordinary skincare, injectable GHK-Cu adds avoidable sterility and dose-variance risk.
Financial Cost (1.5/5.0). GHK-Cu is relatively affordable if you stay topical: many serums and creams cost $30-100/month. Premium cosmetic brands can cost more, but a user does not need the most expensive option to run a basic trial. Injectable peptide vials often cost $60-150/month before syringes, bacteriostatic water, sterile supplies, and third-party testing. Patch programs commonly land around $100-150/month. The cost score stays at 1.5 because a reasonable topical trial is cheap compared with devices, pharmaceuticals, and clinic procedures.
Time / effort burden (2.0/5.0). Topical GHK-Cu is low effort: apply once or twice daily and avoid layering mistakes with acids or retinoids. Patches are also simple if the user accepts the evidence limitations. Injections add meaningful friction: reconstitution, sterile technique, dose measurement, site rotation, sharps disposal, cold storage, and sourcing checks. Post-microneedling use adds another layer because skin is more permeable and infection-prone. The overall burden is low for topical use and moderate for injectable use, which preserves the 2.0 score.
Opportunity Cost (2.0/5.0). GHK-Cu stacks well with the basics, but it can become a distraction when users skip higher-leverage interventions. For skin, sunscreen, sleep, protein, tretinoin or retinoids, collagen peptides, microneedling, and red light therapy are often more established or complementary. For injury, BPC-157 and rehab may be more relevant depending on the tissue. For systemic longevity, exercise, sleep, diet, creatine, and cardiometabolic risk management beat speculative peptide injections. The opportunity-cost score stays at 2.0 because topical use rarely crowds out much, while injection protocols can consume attention.
Dependency / withdrawal (1.0/5.0). GHK-Cu has no known dependency or withdrawal syndrome. It does not act like a stimulant, opioid, benzodiazepine, corticosteroid, or GLP-1 drug where discontinuation can create a recognizable rebound pattern. Stopping topical GHK-Cu should mainly mean that skin gradually returns toward its baseline collagen-turnover and barrier-support state. Stopping injections should remove the exogenous signal without craving or withdrawal. The v0 floor of 1.0 is preserved.
Reversibility (1.5/5.0). GHK-Cu is mostly reversible. Topical and patch effects fade as the skin renews. Injection-site irritation, bruising, or discoloration usually resolves if exposure stops, assuming the product was sterile and correctly dosed. The reason reversibility is 1.5 rather than 1.0 is not permanent damage from the molecule itself; it is the slow fade of collagen-related gains and the fact that contaminated or poorly prepared injectable products can create consequences unrelated to clean GHK-Cu biology. Route quality drives the residual risk.
Verdict
GHK-Cu is a 5.9/10 fit for skin beauty, wound healing, recovery repair, especially for readers who can match the protocol to topical route, copper sensitivity, wound status, and sterile sourcing. The best evidence anchors are Mulder et al. 1994, which Multicenter randomized evaluator-blinded diabetic ulcer trial; 98.5% median area closure versus 60.8% vehicle; lower ulcer infection incidence, and Pickart et al. 2015, which Review of GHK skin regeneration, collagen, glycosaminoglycans, immune-cell attraction, and gene-expression pathways. GHK-Cu is a human copper-binding tripeptide with the best evidence for topical skin repair and wound healing, including Mulder 1994 diabetic ulcer data showing 98.5% median closure versus 60.8% vehicle.
✅ Best for: Adults 40+ with photoaged, thinning, or collagen-depleted skin who want a low-friction topical repair signal; people recovering from microneedling, laser, chemical peels, or irritation-prone cosmetic procedures with clinician-cleared products; early androgenic thinning users who want an adjunct to minoxidil, microneedling, or red light therapy; chronic or diabetic wound contexts only under medical supervision, especially given Mulder 1994; and peptide-community users who understand that systemic injection is experimental, source carefully, and do not confuse gene-expression evidence with proven longevity outcomes.
❌ Avoid if: You have Wilson's disease, known copper overload, unexplained high copper markers, active malignancy without clinician clearance, pregnancy, or lactation. Avoid topical GHK-Cu over suspicious skin lesions or known cutaneous malignancy. Avoid injectable GHK-Cu if you cannot verify sterility, endotoxin, peptide identity, and copper content through independent testing. Athletes should check GlobalDRO or their anti-doping authority because WADA S0 can create uncertainty for non-approved systemic substances. Also avoid if you expect caffeine-like felt effects or want proven systemic longevity, cognition, or stem-cell activation.
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Skin / Beauty: 9.0/10
Score: 9.0/10GHK-Cu scores 9.0/10 for skin beauty, with the best signal coming from Mulder et al. 1994. Topical GHK-Cu keeps its v0 score because cosmetic skin remains the strongest lane: wrinkle, firmness, collagen, elastin, keratinocyte, and barrier mechanisms converge in human and ex vivo evidence. Use Mulder 1994 for wound-adjacent clinical tissue repair and Pickart 2015 for the skin-regeneration review framing. The score stays bounded because GHK-Cu evidence for skin beauty can depend on topical route, copper sensitivity, wound status, and sterile sourcing. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Wound Healing: 8.0/10
Score: 8.0/10For wound healing, GHK-Cu lands at 8.0/10 because Pickart et al. 2015 supports the core mechanism. GHK-Cu keeps an 8 because topical wound evidence is clinically meaningful, especially Mulder 1994, where diabetic plantar ulcers had 98.5% median area closure versus 60.8% with vehicle. This does not transfer automatically to injectable systemic wound claims. The score stays bounded because GHK-Cu evidence for wound healing can depend on topical route, copper sensitivity, wound status, and sterile sourcing. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Recovery / Repair: 7.0/10
Score: 7.0/10The recovery repair use case earns 7.0/10 for GHK-Cu, anchored by Pickart et al. 2014. The v0 score is preserved because collagen remodeling, angiogenesis signaling, keratinocyte proliferation, and fibroblast support are consistent across topical and cellular evidence. Pollard 2005 supports fibroblast growth-factor effects in normal and irradiated fibroblasts, but human recovery outcomes outside skin remain under-tested. The score stays bounded because GHK-Cu evidence for recovery repair can depend on topical route, copper sensitivity, wound status, and sterile sourcing. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Anti-Inflammatory: 7.0/10
Score: 7.0/10Anti Inflammatory is a 7.0/10 fit for GHK-Cu, based on the evidence summarized in Pickart L, Margolina 2018. The v0 anti-inflammatory score is retained because copper-tripeptide biology intersects with IL-6, TGF-beta, tissue remodeling, and skin irritation pathways. Hostynek 2011 supports transdermal delivery as an anti-inflammatory route, while Li 2016 found lower irritation signals for GHK-Cu than inorganic copper salts. The score stays bounded because GHK-Cu evidence for anti inflammatory can depend on topical route, copper sensitivity, wound status, and sterile sourcing. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Neuroprotection: 7.0/10
Score: 7.0/10Evidence puts GHK-Cu at 7.0/10 for neuroprotection, mainly through Pickart et al. 2012. The score is preserved, but the claim is tempered: Tucker 2024 reported intranasal GHK-Cu benefits in a 5xFAD mouse model, and Zhang 2018 supports neuroprotection in rats. Human cognitive or neurodegeneration trials are still missing. The score stays bounded because GHK-Cu evidence for neuroprotection can depend on topical route, copper sensitivity, wound status, and sterile sourcing. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Longevity / Lifespan: 6.5/10
Score: 6.5/10A 6.5/10 longevity rating fits GHK-Cu, since Li et al. 2015 points to a real but bounded effect. The v0 longevity score is preserved but explicitly bounded: Pickart 2014 and Pickart 2018 describe broad gene-expression effects, but no human lifespan, healthspan, or systemic injection RCT validates a longevity outcome. The score stays bounded because GHK-Cu evidence for longevity can depend on topical route, copper sensitivity, wound status, and sterile sourcing. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Stem Cell Support: 6.5/10
Score: 6.5/10The practical stem cell read is 6.5/10 for GHK-Cu, with Hostynek et al. 2011 setting the ceiling. This remains a tissue-niche score, not a systemic stem-cell promise. Kang 2009 found increased p63 positivity and integrin expression in keratinocytes, while Jose 2014 showed GHK-modified hydrogels enhanced mesenchymal stromal-cell trophic factor secretion. The score stays bounded because GHK-Cu evidence for stem cell can depend on topical route, copper sensitivity, wound status, and sterile sourcing. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Antioxidant / Oxidative Stress: 6.5/10
Score: 6.5/10GHK-Cu reaches 6.5/10 for antioxidant when the goal matches the population in Hostynek et al. 2010. GHK-Cu keeps the antioxidant score because copper handling, SOD-related biology, and gene-expression analyses point in the same direction. Pickart 2012 reviewed oxidative-stress and neuroinflammation pathways, but antioxidant status has not been proven as a clinical endpoint in large human trials. The score stays bounded because GHK-Cu evidence for antioxidant can depend on topical route, copper sensitivity, wound status, and sterile sourcing. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Nerve Regeneration: 6.0/10
Score: 6.0/10For readers tracking nerve regeneration, GHK-Cu deserves 6.0/10 because Kang et al. 2009 gives the strongest anchor. The v0 score remains because GHK-related nerve outgrowth and neuronal-protection signals exist, but mostly outside direct human GHK-Cu trials. Zhang 2018 supports neuroprotective signaling in a rat hemorrhage model; human nerve-regeneration use should be treated as experimental. The score stays bounded because GHK-Cu evidence for nerve regeneration can depend on topical route, copper sensitivity, wound status, and sterile sourcing. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Geriatric / Aging Population: 6.0/10
Score: 6.0/10The evidence-weighted call is 6.0/10 for GHK-Cu in geriatric, led by Jose et al. 2014. Age-related decline in endogenous GHK and cellular repair signaling supports the preserved geriatric score, especially in older skin. Pickart 2015 and He 2024 support age-repair and fibrosis mechanisms, but clinical geriatric outcomes are not established. The score stays bounded because GHK-Cu evidence for geriatric can depend on topical route, copper sensitivity, wound status, and sterile sourcing. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Injury Recovery: 6.0/10
Score: 6.0/10GHK-Cu has a 6.0/10 injury recovery case because Lau SJ, Sarkar 1981 supports a plausible benefit. Injury recovery keeps the v0 score because topical and wound-bed evidence is real, while systemic sports-injury or tendon-injury use is not RCT-proven. Mulder 1994 is the clinical support point; Li 2015 supports enhanced delivery after microneedling. The score stays bounded because GHK-Cu evidence for injury recovery can depend on topical route, copper sensitivity, wound status, and sterile sourcing. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Healthspan: 6.0/10
Score: 6.0/10The strongest healthspan argument for GHK-Cu is worth 6.0/10, with Schlesinger et al. 1977 as the anchor. The healthspan score remains a mechanism-weighted 6. Pickart 2018 summarizes protective gene data across repair and inflammation pathways, but the audit found no recent human RCT or meta-analysis that upgrades systemic healthspan confidence. The score stays bounded because GHK-Cu evidence for healthspan can depend on topical route, copper sensitivity, wound status, and sterile sourcing. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Telomere / DNA Repair: 6.0/10
Score: 6.0/10In telomere dna, GHK-Cu rates 6.0/10 because Pickart L, Thaler 1977 supports selective use. The v0 DNA-repair score is preserved because Pickart 2014 reports DNA-repair gene upregulation patterns. This is not equivalent to demonstrated telomere extension, lower cancer incidence, or longer lifespan in humans. The score stays bounded because GHK-Cu evidence for telomere dna can depend on topical route, copper sensitivity, wound status, and sterile sourcing. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Respiratory: 5.5/10
Score: 5.5/10GHK-Cu is a 5.5/10 option for respiratory, especially where the context resembles Pickart et al. 1980. The respiratory score stays at 5.5 because COPD and fibrosis signals are gene-expression or preclinical rather than clinical GHK-Cu trials. Campbell 2012 reported reversal of an emphysema-related gene signature, and He 2024 adds aged-fibroblast fibrosis context. The score stays bounded because GHK-Cu evidence for respiratory can depend on topical route, copper sensitivity, wound status, and sterile sourcing. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
| Use Case | Score | Summary |
|---|---|---|
| ○ Hair / Nail Health Primary | 4.5 | Hair-nail stays at 4.5 because GHK-Cu is common in hair products and has follicle-adjacent mechanisms, but direct human hair-regrowth trial support is much weaker than minoxidil or red light therapy. Pickart 2018 reviews follicle and skin regeneration signals. |
| ○ Cardiovascular | 4.5 | The cardiovascular score is unchanged because fibrinogen, antioxidant, and fibrosis pathways are relevant but indirect. Pickart 2014 discusses fibrinogen and tissue-repair genes, but no human cardiovascular endpoint trial supports risk reduction. |
| ○ Gut Health / Microbiome | 4.5 | Gut-health stays exploratory. GHK reviews mention gastrointestinal lining repair and tissue remodeling, but the evidence is not direct enough for a higher score. Pickart 2015 supports general tissue repair framing, not a clinical gut protocol. |
| ○ Cellular Senescence | 4.5 | Cellular senescence keeps a 4.5 because He 2024 reports aged-fibroblast and myofibroblast senescence mechanisms, and Pickart reviews discuss youthful gene-expression patterns. Human senescence-marker trials are missing. |
| ○ Immune Function | 4.0 | Immune-function keeps a low-to-moderate score because GHK-Cu affects wound immune recruitment and inflammatory cytokine signaling, but no immune-resilience trial exists. Pickart 2015 is the best review-level support. |
| ○ Cognition / Focus | 4.0 | Cognition remains a 4 because evidence is preclinical or indirect. Tucker 2024 reported attenuation of Alzheimer's-like features in mice, and Pickart 2012 discusses cognitive-health mechanisms, but human focus data is absent. |
| ○ Bone / Joint Health | 4.0 | Bone-joint remains speculative relative to skin. GHK-Cu supports collagen and tissue repair biology, and Pickart reviews mention bone repair in preclinical contexts, but clinical osteoarthritis, fracture, or joint-pain trials are not established. Pickart 2018 is the mechanism source. |
| ○ Acute Pain Relief | 4.0 | Acute-pain remains low because any analgesic effect is indirect through inflammation and tissue repair. Pickart 2018 mentions anti-pain activity in protective-action framing, but no acute-pain RCT supports routine use. |
| ○ Neuroplasticity | 4.0 | Neuroplasticity remains exploratory. GHK-related neuroprotection and VEGFA pathway signals exist in animal work, including Zhang 2018, but no human neuroplasticity endpoint trial exists for GHK-Cu. |
| ○ Anxiety | 4.0 | Anxiety stays at 4 because v0 GABAergic and anxiolytic framing is based on preclinical work and review summaries, not human psychiatric trials. Pickart 2018 mentions anti-anxiety activity, but clinical evidence is weak. |
| ○ Memory | 4.0 | Memory remains a 4 because Alzheimer's mouse and neuronal-injury models do not yet translate into human memory outcomes. Tucker 2024 is the newest signal, and it should be read as preclinical. |
| ○ Chronic Pain Management | 4.0 | Chronic-pain stays at 4 because anti-inflammatory and anti-fibrotic mechanisms could matter in painful tissue remodeling, but human pain trials are not confirmed. He 2024 supports fibrosis biology, not analgesia. |
| ○ Traumatic Brain Injury | 4.0 | TBI remains low and exploratory. Zhang 2018 supports neuronal apoptosis protection after brain hemorrhage in rats, but traumatic-brain-injury outcomes in humans are untested. |
| ○ Mood / Emotional Regulation | 3.5 | Mood keeps a 3.5 because GHK-Cu has indirect anti-inflammatory and neuroprotective signals, but no direct antidepressant or mood RCT. Pickart 2012 supports a cognitive-health mechanism review, not mood efficacy. |
| ○ Stress / Resilience | 3.0 | Stress-resilience stays at 3 because antioxidant and repair pathways may buffer biological stress, but the outcome is not measured directly. Pickart 2014 supports gene-repair framing only. |
| ○ Depression | 3.0 | Depression remains a 3 because no clinical antidepressant evidence exists. Mechanistic overlap with inflammation and neuroprotection is not enough for a stronger score. Pickart 2012 is supportive background only. |
| ○ Muscle Growth / Hypertrophy | 3.0 | Muscle-growth stays low because GHK-Cu is not a direct anabolic. Collagen and connective-tissue support may help recovery context, but hypertrophy evidence is absent. Pickart 2018 supports tissue-remodeling biology, not muscle gain. |
| ○ Energy / Fatigue | 3.0 | Energy remains a 3 because mitochondrial and repair-gene claims are indirect. No human fatigue, ATP, or performance endpoint trial supports GHK-Cu for energy. Pickart 2018 is the review-level background. |
| ○ Mitochondrial | 3.0 | Mitochondrial stays low-to-moderate because GHK-Cu affects copper biology and gene-expression pathways, but human mitochondrial-function endpoints are not established. Pickart 2018 provides only review-level support. |
| ○ Autophagy | 3.0 | Autophagy remains a 3 because Pickart 2018 discusses proteasome and cell-cleaning pathways, but no direct human autophagy-marker trial exists. |
Frequently Asked Questions
What is GHK-Cu and how does copper-peptide binding actually work?
GHK-Cu is glycyl-L-histidyl-L-lysine bound to Cu2+, a copper complex that acts mainly as a tissue-repair and copper-delivery signal. Lau 1981 characterized copper binding, while Pickart 2015 summarizes collagen, glycosaminoglycan, immune-recruitment, and gene-expression pathways. In practice, the molecule is strongest where copper-dependent repair enzymes and skin remodeling are already active.
What is the difference between GHK-Cu topical, injection, and patches?
Topical GHK-Cu has the strongest evidence because it directly targets skin and wound tissue. Hostynek 2011 showed copper tripeptide skin penetration, and Li 2015 showed microneedles greatly increased delivery. Subcutaneous injection has no human RCTs. Patches are lower friction but rely heavily on company-funded pharmacokinetic claims rather than independent endpoint trials.
What is the evidence for GHK-Cu on skin and hair?
Skin evidence is stronger than hair evidence. Mulder 1994 showed diabetic ulcer closure benefits with topical GHK-Cu, and Pickart 2018 reviews collagen, elastin, follicle, and repair pathways. Hair claims are plausible as adjunctive cosmetic support, but direct hair-regrowth evidence is much weaker than minoxidil, finasteride, or red light therapy.
Does GHK-Cu actually work for systemic longevity and DNA repair?
Systemic longevity is a mechanistic bet, not a proven human outcome. Pickart 2014 reports DNA-repair and gene-expression changes, and Pickart 2018 expands that review. But the audit found no newer GHK-Cu-specific human RCT or meta-analysis large enough to upgrade systemic anti-aging claims.
Does GHK-Cu really activate stem cells?
GHK-Cu supports stem-cell-marker activity in skin models, but it is not proven to mobilize systemic stem cells in humans. Kang 2009 found increased p63 positivity and integrin expression in keratinocytes. Jose 2014 showed GHK-modified hydrogels increased trophic factor secretion from mesenchymal stromal cells. That supports local tissue-niche activity, not whole-body regeneration claims.
Is gray-market injectable GHK-Cu safe and how do I source it?
The main injectable risk is supply chain, not topical molecule toxicity. The audit found no FDA-approved therapeutic GHK-Cu product and noted FDA 503A bulk-substance status is still in transition. Use only legally compounded sterile product where available, with third-party mass-spec, sterility, endotoxin, and copper-content testing. Anonymous research-chemical vials are a different risk category from regulated cosmetic topicals.
Can I stack GHK-Cu with Matrixyl, retinol, and collagen supplements?
Yes, but sequence the skincare intelligently. GHK-Cu pairs well with Matrixyl, niacinamide, and oral collagen peptides, while retinoids are usually better on alternate nights because irritation and pH conflicts can reduce tolerability. GHK-Cu is also commonly paired with BPC-157 in peptide communities, but combined injection protocols compound sourcing and sterility risks.
Who should avoid GHK-Cu?
Avoid systemic GHK-Cu if you have Wilson's disease, known copper overload, unexplained high copper markers, pregnancy, lactation, or active malignancy unless a clinician specifically clears it. Avoid topical use near suspicious or malignant skin lesions. Athletes should also check anti-doping status because WADA S0 can create uncertainty for non-approved systemic substances even when the compound is not named.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Dimensions changed | New score |
|---|---|---|
| Independent dermatology RCT replicates strong firmness and wrinkle endpoints with transparent funding | Efficacy 3.5 to 4.0; Evidence 3.0 to 3.5 | 6.8 / 10 💪 Strong recommend |
| First human injection pharmacokinetic and safety trial confirms clean systemic exposure without copper accumulation | Evidence 3.0 to 3.5; Bioindividuality 3.5 to 4.0 | 6.6 / 10 💪 Strong recommend |
| Case report cluster links chronic injectable use to copper neurotoxicity or contaminated-vial harms | Safety 2.0 to 3.5 | 5.1 / 10 👍 Worth trying |
| Randomized hair-regrowth trial confirms density endpoint versus minoxidil-adjacent comparator | Efficacy 3.5 to 3.8; Breadth 3.5 to 3.8 | 6.6 / 10 💪 Strong recommend |
| Independent lab fails to replicate key fibroblast collagen and keratinocyte stemness signals | Evidence 3.0 to 2.3; Efficacy 3.5 to 3.0 | 5.3 / 10 👍 Worth trying |
| FDA or dermatology authority publishes a GHK-Cu-specific therapeutic caution for systemic compounding | Safety 2.0 to 3.0; Evidence 3.0 to 2.7 | 5.4 / 10 👍 Worth trying |
Key Evidence Sources
- Mulder GD et al. 1994 - Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-L-histidyl-L-lysine copper, Wound Repair and Regeneration. Multicenter randomized evaluator-blinded diabetic ulcer trial; 98.5% median area closure versus 60.8% vehicle; lower ulcer infection incidence.
- Pickart L et al. 2015 - GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration, BioMed Research International. Review of GHK skin regeneration, collagen, glycosaminoglycans, immune-cell attraction, and gene-expression pathways.
- Pickart L et al. 2014 - GHK and DNA: Resetting the Human Genome to Health, BioMed Research International. Gene-expression review reporting DNA repair, antioxidant, tissue repair, and fibrosis-related pathway modulation; not a human endpoint trial.
- Pickart L et al. 2012 - The Human Tripeptide GHK-Cu in Prevention of Oxidative Stress and Degenerative Conditions of Aging, Oxidative Medicine and Cellular Longevity. Review connecting GHK-Cu with oxidative stress, copper homeostasis, neuroinflammation, and aging-related mechanisms.
- Pickart L, Margolina A 2018 - Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data, International Journal of Molecular Sciences. Review of GHK-Cu regenerative and protective pathways, including skin, hair, COPD fibroblast, DNA repair, and proteasome framing.
- Hostynek JJ et al. 2011 - Human skin penetration of a copper tripeptide in vitro as a function of skin layer, Inflammation Research. Ex vivo human skin diffusion study; quantified dermatomed-skin copper permeability and tissue retention from GHK-Cu.
- Hostynek JJ et al. 2010 - Human skin retention and penetration of a copper tripeptide in vitro as function of skin layer towards anti-inflammatory therapy, Inflammation Research. Ex vivo delivery study supporting topical and transdermal delivery rationale for copper tripeptide.
- Li H et al. 2015 - Microneedle-Mediated Delivery of Copper Peptide Through Skin, Pharmaceutical Research. Microneedle pretreatment enabled 134 +/- 12 nmol peptide and 705 +/- 84 nmol copper permeation through human skin in 9 hours.
- Kang YA et al. 2009 - Copper-GHK increases integrin expression and p63 positivity by keratinocytes, Archives of Dermatological Research. Keratinocyte and skin-equivalent study; increased PCNA, p63, integrin alpha6, and beta1 expression.
- Jose S et al. 2014 - Enhanced trophic factor secretion by mesenchymal stem/stromal cells with GHK-modified alginate hydrogels, Acta Biomaterialia. Preclinical biomaterials study supporting GHK-related trophic factor secretion from mesenchymal stromal cells.
- Lau SJ, Sarkar B 1981 - The interaction of copper(II) and glycyl-L-histidyl-L-lysine, a growth-modulating tripeptide from plasma, Biochemical Journal. Copper-binding chemistry study; supports GHK-Cu complex formation and copper coordination mechanism.
- Schlesinger DH et al. 1977 - Growth-modulating serum tripeptide is glycyl-histidyl-lysine, Experientia. Early identity paper confirming the growth-modulating serum tripeptide sequence as GHK.
- Pickart L, Thaler MM 1977 - Alteration in biological properties of human albumin during storage, Biochemical and Biophysical Research Communications. Early GHK discovery-lineage paper on biological properties of human albumin fractions.
- Pickart L et al. 1980 - Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells, Nature. Classic Nature paper proposing GHK as a copper-uptake facilitator in cultured cells.
- Pollard JD et al. 2005 - Effects of Copper Tripeptide on the Growth and Expression of Growth Factors by Normal and Irradiated Fibroblasts, Archives of Facial Plastic Surgery. In vitro fibroblast study in normal and irradiated fibroblasts; supports tissue-repair and post-radiation skin biology.
- Ogorek R et al. 2025 - Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes?, Molecules. Modern delivery review; highlights hydrophilicity and limited stratum-corneum permeation challenges for GHK-Cu.
- He Q et al. 2024 - The naturally occurring peptide GHK reverses age-related fibrosis by modulating myofibroblast function, Aging Pathobiology and Therapeutics. 2024 fibrosis commentary and preclinical data; useful for mechanism update, not a human efficacy trial.
- Tucker et al. 2024 - Behavioral and neuropathological features of Alzheimer's disease are attenuated in 5xFAD mice treated with intranasal GHK peptide. Animal model signal for intranasal GHK; does not establish human cognitive efficacy.
- FDA 2026 - 503A bulk substances update for GHK-Cu. Authority signal: no FDA-approved therapeutic indication; 503A bulk-substance posture is in transition with PCAC consultation expected.
- AAD - Wrinkles and sun damage can be treated. Dermatology authority context: AAD mentions growth factors/peptides generally but has no GHK-Cu-specific recommendation.
Holistic Evidence Profile
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Medium
Citations: Mulder 1994, Hostynek 2011, Li 2015, Pickart 2015, Pickart 2018, Ogorek 2025, He 2024, Tucker 2024
Pre-RCT-Era Pharmacology and Use
Confidence: Medium
Citations: Pickart 1973, Schlesinger 1977, Pickart 1980, Lau 1981, Maquart 1988
Traditional Medicine Systems
Confidence: Limited
Holistic Evidence for GHK-Cu
Modern, historical, and traditional lenses agree only at the broad level: copper biology matters in tissue repair. They diverge sharply on GHK-Cu itself. Modern literature supports topical skin and wound applications, historical research explains the peptide-copper mechanism, and traditional use supports only broad copper exposure. Honest synthesis: GHK-Cu is worth trying topically for skin repair, but systemic injection, longevity, cognition, and stem-cell claims remain experimental.
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- Copper Baseline (pre-protocol) During | Expected Watch
- ALT During | Expected Stable
- AST During | Expected Stable
- WBC During | Expected Stable
Pulse Dimensions to Watch
- Body During | Expected Up | Primary
- Energy During | Expected Stable | Tertiary
- Calm During | Expected Stable | Tertiary
Subjective Signals (Daily Voice Card)
- Skin Healing Scale 1-5 | During | Expected Up
- Injection-Site Irritation Scale 1-5 | During | Expected Watch
- Hair Or Nail Changes Scale 1-5 | During | Expected Watch
Red Flags: Stop and Consult
- Injection-site infection
- Copper excess symptoms: nausea, metallic taste, abdominal pain
Other interventions for Skin & Beauty
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–3.6, Caution 3.7–4.7, Neutral 4.8–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–7.9, Top-tier 8.0+.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 2.175 − 0.930 = 1.245
Formula v0.5 maps EV = 0 to score 5.0. Above neutral, 1 EV point equals 1 score point. Below neutral, 1 EV point equals about 0.71 score points, so EV = −7 reaches 0.0 while EV = +5 reaches 10.0. Both sides use the full 5-point half-scale.
Score = 5 + (1.245 / 5) × 5 = 6.2 / 10
